Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
MaxCyte Highlights the Use of Large Scale Transient Transfection for High Throughput Screening in Biologically Relevant Cells in an Upcoming Educational Webinar Presentation
April 24, 2013
Case Study of CFTR Cell-based Screening to be presented by Dr. Jinliang Sui of Flatley Discovery Lab
Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting an educational webinar entitled "Streamlining HTS: Ion Channel, GPCR, and Transporter Assays in Biologically Relevant Cells using Large Scale Transfection" on Wednesday, April 24, 2013, from 11:00 AM 12:00 PM EDT. Dr. Jinliang Sui, Senior Director of HTS & Bioinformatics at Flatley Discovery Lab, will present their research to develop a novel cellular assay for the identification of CFTR modulators using MaxCyte scalable transfection of human bronchial epithelial cells. In addition, Dr. James Brady, Director of Technical Applications at MaxCyte, will discuss the use of large scale transient transfection in primary cells and assays for other receptor types targeted in drug discovery, such as ion channels and G protein-coupled receptors (GPCRs).
This live scientific webinar will focus on the use of MaxCytes proprietary large scale transfection technology in advanced high throughput cell-based screening. "Performing high throughput screening assays in standard cell lines simply because they are easy to transfect does not always translate into meaningful results," says Dr. Karen Donato, EVP of Global Business Development and Marketing at MaxCyte. "The MaxCyte STX has the quality, scalability, and cell type compatibility that are all essential for performing more biologically relevant screens. MaxCyte transfection is a perfect fit for todays cellbased screening laboratories to generatemore predictive assays to identify high quality drug candidates."
"MaxCyte began in the area of cell therapy in which high quality transfection of human primary cells is critical. We have applied and expanded that expertise to advance the field of drug discovery and development," says Douglas Doerfler, President, and CEO of MaxCyte. "MaxCyte technology is unique in its ability to transiently transfect cells previously thought of as difficult-to-transfect. Leading researchers, like the team at Flatley Discovery Lab, recognize the high level of performance and scalability of MaxCytes technology. The creativity and innovation of the team at Flatley has resulted in the generation of novel, meaningful results. This webinar will demonstrate the potential of MaxCyte technology to improve the predictability of cellular screening and the quality of identified candidates."
Interested participants can find out more information and register for the webinar on MaxCytes web site, www.maxcyte.com, to learn how MaxCyte Scalable Transfection Systems can accelerate and improve high throughput receptor screening using large scale, transient transfection of relevant cells.